1. Cystatin C and Albuminuria as Risk Factors for Development of CKD Stage 3: The Multi- Ethnic Study of Atherosclerosis (MESA) 
Shani Shastri, MD, MS, Ronit Katz, DPhil, Michael G. Shlipak, MD, MPH, Bryan Kestenbaum, MD, MS, Carmen A. Peralta, MD, MAS, Holly Kramer, MD, David R. Jacobs, PhD, Ian H. de Boer, MD, MS, Mary Cushman, MD, David Siscovick, MD, MPH, Mark J. Sarnak, MD, MS 
American Journal of Kidney Diseases 
Volume 57, Issue 6, Pages (June 2011)
DOI: /j.ajkd
Copyright © 2011 National Kidney Foundation, Inc. Terms and Conditions

2. Figure 1
Cystatin C spline evaluates the shape of the relationship with incident rate ratios of chronic kidney disease stage 3 after adjusting for age, sex, and race and excluding the top and bottom 2.5%. Conversion factor for units: cystatin C in mg/L to nmol/L, ×74.9.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2011 National Kidney Foundation, Inc. Terms and Conditions

3. Figure 2
Annual unadjusted rate of incident chronic kidney disease stage 3 by quartiles of cystatin C and presence of microalbuminuria. Conversion factor for units: cystatin C in mg/L to nmol/L, ×74.9. Abbreviation: MA, microalbuminuria.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2011 National Kidney Foundation, Inc. Terms and Conditions